Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Total Liabilities (2023 - 2025)

CG Oncology's Total Liabilities history spans 3 years, with the latest figure at $39.0 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 82.03% year-over-year to $39.0 million; the TTM value through Dec 2025 reached $39.0 million, up 82.03%, while the annual FY2025 figure was $39.0 million, 82.03% up from the prior year.
  • Total Liabilities reached $39.0 million in Q4 2025 per CGON's latest filing, down from $42.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $107.6 million in Q3 2023 to a low of $10.2 million in Q1 2024.
  • Average Total Liabilities over 3 years is $41.7 million, with a median of $27.3 million recorded in 2025.
  • Peak YoY movement for Total Liabilities: crashed 88.19% in 2024, then surged 169.22% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $14.5 million in 2023, then skyrocketed by 47.61% to $21.4 million in 2024, then surged by 82.03% to $39.0 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Total Liabilities are $39.0 million (Q4 2025), $42.3 million (Q3 2025), and $31.1 million (Q2 2025).